← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Harlingene Life Sciences Llc
Doylestown, PA
$1,900,000
Total funding
3
Grants
Funding over time
peak $1M · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,900,000 · 3
By mechanism
R42$1,000,000 · 1
R41$900,000 · 2
Investigators at Harlingene Life Sciences Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$1,000,000
R42 · FY2025 · AI
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$300,000
R41 · FY2023 · AI
Hepatoselective Dihydroquinolizinone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection$300,000
R41 · FY2024 · AI
Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction$300,000
R41 · FY2022 · AI